Bronchiolitis Obliterans Syndrome Clinical Trial
— CLADOfficial title:
Evaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants Recipients
NCT number | NCT02863835 |
Other study ID # | 16/LO/0198 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2016 |
Est. completion date | June 2017 |
Verified date | May 2018 |
Source | Guy's and St Thomas' NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Electrical impedance tomography (EIT) is non-invasive and provides functional imaging of the lung and it could be a useful tool to diagnose chronic lung allograft dysfunction (CLAD) and specially Bronchiolitis Obliterans Syndrome (BOS). Hence, for this study, the investigators aim to show that EIT would provide an accurate diagnostic CLAD with an ability to to distinguish BOS from Restrictive Allograft Syndrome (RAS) and to stage BOS accurately when compared to FEV1 the current gold standard. The investigators are also aiming to provide physiological data in lung transplant recipients with chronic rejection.
Status | Completed |
Enrollment | 50 |
Est. completion date | June 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Bilateral lung transplant recipient - Time from lung transplantation > 6 months - A chest CT scan (HRCT) performed as part of their standard care in the last 3 months - A bronchoscopy with BAL and Biopsies performed as part of their standard care in the last 3 months - For group with CLAD: a drop in lung function assessed on FEV1 or FVC - For group without CLAD: an unchanged lung function Exclusion Criteria: - Pregnancy - Body mass index > 40kg/m2 - Significant physical or psychiatric comorbidity that would prevent compliance with trial protocol - Allergy to salbutamol - Patient with intra-bronchial or intra-tracheal metallic stent - Evidence of acute infection or acute cellular rejection. In addition 10 healthy volunteers will be recruited |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Guys and St Thomas NHS Foundation | London |
Lead Sponsor | Collaborator |
---|---|
Guy's and St Thomas' NHS Foundation Trust | ADIR Association |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of chronic lung allograft dysfunction in lung transplant recipients identified with EIT | Using EIT to diagnose chronic lung allograft dysfunction in lung transplant recipients | 1 day | |
Primary | Restrictive and obstructive phenotypes in recipients of lung transplants. | Using EIT to distinguish between restrictive and obstructive different phenotypes in recipients of lung transplants | 1 day | |
Secondary | Change in EIT results following administration of salbutamol and CPAP | Following administration of salbutamol whilst using CPAP taking EITresults to determine if there is a change in the lungs | 1 day | |
Secondary | Correlation EIT results and chest-CT results | Comparing Lung measurements taken during the EIT test with the CT results of the participants to ascertain if there is any correlation | 1 day | |
Secondary | Neural respiratory drive (EMGpara) of lung transplant recipients | Comparing lung measurements taken during the EIT test with those taken during neural respiratory drive during the intervention | 1 day | |
Secondary | Correlation between EIT and neural respiratory drive results with breathlessness | Comparing lung measurements taken during the EIT test with the Neural respiratory drive results taken and the participants breathlessness | 1 day | |
Secondary | Correlation of EIT results found in obstructive and restrictive allograft syndrome | Comparing the obstructive allograft syndrome EIT results to the restrictive allograft syndrome results. | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01807975 -
Forced Oscillation Versus Spirometry in Diagnosing Post Pulmonary Transplant Bronchiolitis Obliterans Syndrome
|
N/A | |
Completed |
NCT01009619 -
Azithromycin in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Recruiting |
NCT04391335 -
Novel Pulmonary Function Measures for Diagnosis of Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem-Cell Transplantation in Children
|
||
Recruiting |
NCT05922761 -
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
|
Phase 2 | |
Recruiting |
NCT05250037 -
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
|
||
Enrolling by invitation |
NCT04039347 -
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
|
Phase 3 | |
Recruiting |
NCT05413356 -
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
|
Phase 2 | |
Recruiting |
NCT00774449 -
Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation
|
N/A | |
Terminated |
NCT03978637 -
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT02316392 -
Imaging and Understanding BOS in Lung Transplantation
|
||
Completed |
NCT00528853 -
Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation
|
N/A | |
Recruiting |
NCT06018766 -
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
|
Phase 2 | |
Recruiting |
NCT02669251 -
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT03072849 -
Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation
|
N/A |